Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - March 5, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-03-05 7:00 AM EST | Phio Pharmaceuticals Corp.
Cosmo Announces Strategic R&D Collaboration to Advance AI-Based Detection of Early Neoplasia in Barrett's Esophagus
Dublin, Ireland--(Newsfile Corp. - March 5, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced a strategic Research and Development Agreement with Amsterdam UMC and Eindhoven University of Technology to develop and clinically validate an artificial intelligence (AI)-based computer-aided detection (CADe) system for the identification of early neoplasia in Barrett’s esophagus. The collaboration represents an important step in ex
Healthcare and Hospitals, Health
2026-03-05 1:00 AM EST | Cosmo Pharmaceuticals N.V.
FDA Leadership Headlines at AAMI neXus 2026 Medtech Conference
Arlington, Virginia--(Newsfile Corp. - March 4, 2026) - The Association for the Advancement of Medical Instrumentation (AAMI) officially welcomes speakers from the U.S. Food and Drug Administration (FDA) to its upcoming medical device standards conference, AAMI neXus 2026. Dr. Michelle Tarver, Director of FDA's Center for Devices and Radiological Health (CDRH), w
2026-03-04 8:50 AM EST | Association for the Advancement of Medical Instrumentation
Safe Supply Confirms NIRLAB Drug Analysis Devices Actively Deployed and Under Field Evaluation by Government Stakeholders
Toronto, Ontario--(Newsfile Corp. - March 4, 2026) - Safe Supply Streaming Co Ltd. (CSE: SPLY) (OTCQB: SSPLF) (FSE: QM4) ("Safe Supply" or the "Company"), a pioneer in health, safety, and rapid response technologies, today provided an update on its NIRLAB SA ("NIRLAB") pilot program, confirming that NIRLAB NIRLIGHT spectroscopy drug analysis devices are currently deployed with government stakeholders and are being actively tested in the field. The Company is also reportin
2026-03-04 7:07 AM EST | Safe Supply Streaming Co Ltd.
Numinus Wellness Advises of a Change of Auditor
Vancouver, British Columbia--(Newsfile Corp. - March 3, 2026) - Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, is advising of a change of its auditor. The Company's previous auditor, Horizon Assurance LLP ("Horizon") no longer serves as the Company's auditor, with PKF Antares Professional Corpora
2026-03-03 5:00 PM EST | Numinus Wellness Inc.
Adia Nutrition Announces Submission of Final Revised Protocol for Lower Back Pain Study with AdiaVita
Winter Park, Florida--(Newsfile Corp. - March 3, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), a company focused on regenerative medicine and therapeutic solutions, today announced that its subsidiary, Adia Med of Winter Park, LLC, has submitted its final revised protocol to the Institutional Review Board (IRB) for the lower back pain clinical study.
Healthcare and Hospitals, Health
2026-03-03 10:20 AM EST | Adia Nutrition Inc.
Canadian Pulmonary Fibrosis Foundation: Oxygen Therapy Saves Lives and Health Care Dollars
Toronto, Ontario--(Newsfile Corp. - March 3, 2026) - Oxygen therapy is a lifeline for people living with chronic lung diseases like pulmonary fibrosis. It reduces hospitalizations and improves quality of life. Yet across Canada, access to medically necessary oxygen therapy depends on where a person lives, inconsistent qualification criteria and, in some cases, one's ability to pay. The Canadian Pulmonary Fibrosis Foundation (CPFF) is calling on health authorities to designate supplemental oxy
Healthcare and Hospitals, Health
2026-03-03 9:21 AM EST | Canadian Pulmonary Fibrosis Foundation
Jeffrey W. Sherman, MD, Joins DIMERx Board to Advance Next-Generation, Non-Addictive Pain Therapies
San Francisco, California--(Newsfile Corp. - March 3, 2026) - DIMERx, Inc. ("DIMERx" or "the Company"), is a clinical-stage biopharmaceutical company dedicated to addressing the public-health crisis of drug abuse and dependence, with a portfolio of first-in-class, dimer-based pain therapeutics engineered to deliver effective analgesia without the addiction liabilities of conventional opioids. The Company announced the appointment of Jeffrey W. Sherman, MD, FACP, to its Board of Directors. Dr.
Biotechnology, Pharmaceuticals, Health
2026-03-03 9:00 AM EST | DIMERx INC.
BioHarvest Sciences to Participate in 38th Annual Roth Conference on March 22-24, 2026
British Columbia and Rehovot, Israel--(Newsfile Corp. - March 3, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that management has been invited to attend the 38th Annual Roth Conference taking place on March 22-24, 2026.
Biotechnology, Pharmaceuticals, Health
2026-03-03 8:30 AM EST | BioHarvest Sciences Inc.
Red Light Holland Reports Third Quarter 2026 Results and Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - March 3, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based organization advancing a focused strategy within the legal psychedelic sector, centered on consensual data collection and research and development ("R&D") initiatives designed to expand naturally occurring drug development, understanding of psilocybin use and consumer experie
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-03-03 8:00 AM EST | Red Light Holland Corp.
Delota Reports Financial Results for the Three and Nine Months Ended December 31, 2025
Highlights Total revenue of $8.4 million for Q3 2026 Total System-Wide Revenue of $10.0 million for Q3 2026 30% gross profit margin for Q3 2026 Total revenue of $27.1 million for the Nine Months Ended 2026 Total System-Wide Revenue of $30.9 million for the Nine Months Ended 2026 33% gross profit margin for the Nine Months Ended 2026
Retail, Cannabis, Health, Cannabis Dispensary
2026-03-03 7:30 AM EST | Delota Corp.
Restart Life Announces Collaboration with University of Manitoba's Centre for Food Technology and Research
Vancouver, British Columbia--(Newsfile Corp. - March 3, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that, following the successful acquisition of Holy Crap Foods Inc., it has entered into a collaboration with the University of Manitoba's Richardson Centre for Food Technology and Research (RCFTR) to support a series of food-related scientific studies that will guide the Company's product development road
Technology, Biotechnology, Health
2026-03-03 6:00 AM EST | Restart Life Sciences Corp.
Defence Therapeutics to Showcase Accum Platform at Key International Industry Events in March
Montreal, Quebec--(Newsfile Corp. - March 2, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology company advancing next-generation therapeutics using its proprietary Accum® platform, today outlined its participation in a series of major international industry events taking place in March 2026. These high-profile meetings will provide Defence with multiple opportunities to advance strategic p
Biotechnology, Pharmaceuticals, Health
2026-03-02 3:15 AM EST | Defence Therapeutics Inc.
Delivra Health and Its Brands LivRelief (TM) and Dream Water (TM) Report Results for Second Quarter of Fiscal 2026
Vancouver, British Columbia--(Newsfile Corp. - February 27, 2026) - Delivra Health Brands Inc. (TSXV: DH
Cannabis, Health, Cannabis Extractor, Cannabis Manufacturer
2026-02-27 6:45 PM EST | Delivra Health Brands Inc.
Defence Therapeutics Announces Private Placement of Units for Proceeds of up to $11 Million
Montreal, Quebec--(Newsfile Corp. - February 27, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the launch of a private placement (the "Private Placement") of up to 20,000,000 units (the "Units") at a price of $0.55 per Unit, for aggregate gross proceeds to Defence of up to $11,000,000. Each Unit will be compris
Biotechnology, Pharmaceuticals, Health
2026-02-27 5:00 PM EST | Defence Therapeutics Inc.
Communities Nationwide Rally This March to Support Lifesaving Childhood Cancer Research
Los Angeles, California--(Newsfile Corp. - February 27, 2026) - This March, communities across the country will unite in support of the St. Baldrick's Foundation, the largest charity funder of childhood cancer research grants in the U.S., in a nationwide effort to Conquer Kids' Cancer. From local schools, fire and police departments, pubs and restaurants, workpl
2026-02-27 3:00 PM EST | St. Baldrick's Foundation
First Towers & Fiber Corp. Owns the Largest Dark Fiber Network in Central Mexico
Toronto, Ontario--(Newsfile Corp. - February 27, 2026) - Akanda Corp. (NASDAQ: AKAN) ("Akanda") and its 100% owned subsidiary First Towers & Fiber Corp. ("FTF" or the "Company"), an emerging telecommunications infrastructure developer in Mexico, announced today plans to further expand the leasing of its approximately 700-kilometre dark fiber optic network located in Central Mexico. The network represents the largest dark fiber infrastructure in the region, serving several of Mexico's most
Cannabis, Health, Cannabis Cultivator, Cannabis Manufacturer
2026-02-27 8:30 AM EST | Akanda Corp
Restart Life Sciences Closes Acquisition of Holy Crap Foods
Vancouver, British Columbia--(Newsfile Corp. - February 27, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that it has successfully closed the previously announced acquisition of 100% of the issued and outstanding shares of Holy Crap Foods Inc. ("Holy Crap") pursuant to the definitive agreement dated February 12, 2026, among the Company, Happy Belly Coffee Inc., a subsidiary of Happy Belly Food Group
Technology, Biotechnology, Health
2026-02-27 8:00 AM EST | Restart Life Sciences Corp.
QScreen AI Announces Strategic Financing to Advance Commercialization Initiatives Across North America
Toronto, Ontario--(Newsfile Corp. - February 26, 2026) - QScreen AI Inc (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP), an innovator fusing Quantum-AI technologies to transform health screening and employee wellness, is pleased to announce a non-brokered private placement. The Company intends to issue (the "Offering") of up to 10,000,000 units (each, a "Unit") at a price of C$0.05 per Unit, for aggregate gross proceeds to the Company of up to C$500,000. Each Unit will be comprised of one commo
2026-02-26 5:30 PM EST | QScreen AI Inc.
DiagnosTear Announces Regulatory Approvals in France and Study Initiation with AlyaTec for TeaRx(TM) Red Eye
Vancouver, British Columbia--(Newsfile Corp. - February 26, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a fast-growing innovator in point-of-care ocular diagnostics, is pleased to announce that it has obtained all required regulatory and ethics approvals to proceed with the clinical study of TeaRx™ Red Eye previously announced in a press release dated December 2, 2025. As previously disclosed, the Company initiated a collaboration
2026-02-26 5:00 PM EST | DiagnosTear Technologies Inc.